Author Interviews, Breast Cancer, Genetic Research, Nature / 11.01.2015
Novel Gene Is Potential Therapeutic Target for Triple Negative Breast Cancer
MedicalResearch.com Interview with:
Dr. Pentao Liu PhD and Dr. Walid Khaled PhD
Wellcome Trust Sanger Institute
Cambridgeshire United Kingdom
Medical Research: What is the background for this study? What are the main findings?
Dr. Pentao Liu: The significance of this research is that it aims to tackle the worst type of breast cancer. Triple Negative Breast Cancer (TNBC) has the poorest patient survival rate compared to other forms of breast cancer. At present there are no targeted therapies available for TNBC, leaving the non-specific chemotherapy as the only treatment option. In this study we identify a new key gene in Triple Negative Breast Cancer which could potentially be inhibited for the targeted treatment of TNBC.
In this study we report the identification of a novel gene for Triple Negative Breast Cancer. By analyzing genomics data from 3,000 patients we find BCL11A to be highly expressed in TNBC. We then demonstrate experimentally that upregulation of BCL11A drives tumour development while its downregulation leads to reduction in tumour size. In the experimental mouse model, inactivation of this gene completely abolishes breast tumour development.
























Prof. Bisgaard[/caption]
MedicalResearch.com Interview with:
Professor of Pediatrics Hans Bisgaard, MD, DMSc
Copenhagen Prospective Studies on Asthma in Childhood
